Business Context and Reporting Period
Company: Bovie Medical Corporation (formerly Apyx Medical Corp in metadata, but filing identifies Bovie Medical Corporation)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Bovie Medical Corporation develops, manufactures, and markets medical devices, primarily electrosurgical generators, disposables, and cauteries. The company operates through two main segments: Bovie Medical Corp (U.S.) and Bovie Canada. Products are sold to hospitals, surgical centers, and physician offices via distributors and Original Equipment Manufacturer (OEM) agreements. The company is headquartered in Melville, New York, with manufacturing facilities in Clearwater and St. Petersburg, Florida, and Windsor, Canada.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Net Sales | $26,953,000 | $28,097,000 |
| Gross Profit | $11,855,000 | $11,849,000 |
| Gross Margin | 44.0% | 42.2% |
| Net Income | $596,000 | $1,832,000 |
| Diluted EPS | $0.03 | $0.11 |
| Operating Cash Flow | ($98,000) Used | $743,000 Provided |
| Cash and Equivalents | $2,155,000 | $2,565,000 |
| Working Capital | $10,741,000 | $9,943,000 |
| Total Debt (Long-term + Current) | $5,128,000 | $4,268,000 |
Note: Debt includes a $1.0M line of credit balance and $3.875M mortgage note payable.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 4.1% to $26.95 million. This was driven by a 7.2% drop in generator sales due to reduced capital expenditures by hospitals during the economic recession. International sales also declined 9.6%.
- Profitability Compression: Despite a slight increase in gross profit dollars, Net Income fell 67.5% to $596,000. This was primarily due to the absence of a one-time $1.5 million gain from a contract cancellation with Boston Scientific recorded in 2008.
- Expense Increases: Professional services expenses rose 41.1% (largely due to legal fees for the Erbe lawsuit settlement and SEC compliance). Selling, General, and Administrative (SG&A) expenses increased 3.7% due to a $160,000 legal settlement, facility consolidation costs, and higher taxes.
- Inventory Build-up: Inventory days increased to 172 days (from 144 days in 2008) due to lower sales volume of generator products, which have higher parts counts.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2010 Outlook: Management is "cautiously optimistic" for modest improvement in the second half of 2010, citing improved economic conditions and new product introductions.
- New Products: Received FDA clearance for the ICON VS generator, Resistick II (coated blades), and J-Plasma (ICON GS). The SEER tissue resection device has received orders, though hospital market entry has been slower than anticipated due to complex purchasing procedures.
- Cost Management: Implemented cost-cutting measures in 2009, including suspending employee bonuses and the 401(k) match.
Risks and Contingencies
- Customer Concentration: Arthrex, Inc. accounted for 22% of total revenues in 2009. Loss of this OEM customer would materially adversely affect the business.
- Legal Settlement: Settled a trade secret lawsuit with Erbe USA, Inc. for $160,000, agreeing to a two-year non-solicitation period for Erbe employees and dealers.
- Liquidity: While cash on hand is sufficient for the next year, the company relies on a $8 million revolving credit facility (with $4 million available) and a $1 million equipment line. Covenants require maintaining specific debt-to-equity and debt-service coverage ratios.
- Regulatory: Potential healthcare reform legislation could impose excise taxes on medical devices.
Investor Verification Checklist
- Arthrex Dependency: Verify the status of the OEM agreement with Arthrex (22% of revenue) and any potential renewal risks.
- Inventory Valuation: Assess the risk of obsolescence given the increase in inventory days to 172 and the decline in generator sales.
- Legal Exposure: Confirm no further liabilities exist regarding the Erbe settlement or the potential patent infringement claim by Soring regarding J-Plasma technology.
- Cash Flow Sustainability: Monitor the transition from negative operating cash flow in 2009 to positive flow in 2010, given the reliance on debt financing for facility renovations.
- New Product Adoption: Track actual sales performance of the SEER and J-Plasma devices against management's optimistic projections.